Sheptulin V, et al. - In chronic central serous chorioretinopathy (CSC), researchers assessed the outcome of half-time photodynamic therapy (PDT). Researchers analyzed a total of 114 eyes of 103 patients (81 male; 22 female) with the median age of 49 (28–70). As per data, for patients with chronic CSC with a significant best-corrected visual acuities (BCVA) improvement during the follow-up after the therapy, an effective and safe treatment option is half-time PDT. After 8 weeks, SRF resolution was achieved with a notable improvement of median LogMAR BCVA from 0.22 before PDT to 0.1 at last visit after PDT.